{"version":"1.0","provider_name":"Association Fran\u00e7aise Ataxie de Friedreich","provider_url":"https:\/\/www.afaf.asso.fr","author_name":"Caroline Gaboriau","author_url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/","title":"INFORMATION IMPORTANTE OMAVELOXOLONE - Association Fran\u00e7aise Ataxie de Friedreich","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1ACs9kPE2r\"><a href=\"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/\">INFORMATION IMPORTANTE OMAVELOXOLONE<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.afaf.asso.fr\/2023\/07\/10\/information-importante-omaveloxolone\/embed\/#?secret=1ACs9kPE2r\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0INFORMATION IMPORTANTE OMAVELOXOLONE\u00a0\u00bb &#8212; Association Fran\u00e7aise Ataxie de Friedreich\" data-secret=\"1ACs9kPE2r\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.afaf.asso.fr\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","thumbnail_width":349,"thumbnail_height":144,"description":"La soci\u00e9t\u00e9 Reata Pharmaceuticals, Inc. a d\u00e9pos\u00e9 le 3 Juillet 2023 en France le dossier d\u2019acc\u00e8s pr\u00e9coce pour le SKYCLARYS (omaveloxolone) aupr\u00e8s de la Haute Autorit\u00e9 de Sant\u00e9 (HAS) et de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Les agences ont 3 mois au maximum pour statuer sur cette demande, [&hellip;]"}